Yulia Slavina

Capital shortage prompts Caribou Biosciences to halt allogeneic CAR-T therapy initiatives

Capital shortage prompts Caribou Biosciences to halt allogeneic CAR-T therapy initiatives
Caribou halts allogeneic CAR-T plans

Caribou Biosciences announced it will discontinue its allogeneic CAR-T cell therapy programs due to difficulties in securing the necessary funding to advance these initiatives.

The company stated it is evaluating strategic alternatives as it faces ongoing challenges accessing capital required for further development.

Caribou Biosciences was previously named a finalist for Citeline's 2026 Best Oncology R and D Advance Award for its vispa-cel therapy, according to a recent report. The company had highlighted vispa-cel as a key asset in its pipeline. The latest decision to halt allogeneic CAR-T programs follows ongoing challenges in funding these developments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.